PubMed HealthSearch

Biomedical subjects

I Amaki

Publications and source records attributed to I Amaki.

At least 19 recordsLinked to original sources

Genetic variants of serum albumin in Americans and Japanese.

A collaborative search for albumin genetic variants (alloalbumins) was undertaken by cellulose acetate and agarose electrophoresis at pH 8.6 of the sera of patients at two major medical centers in the United States and of nearly 20,000 blood donors in Japan. Seventeen instances of alloalbuminemia were ascertained, and seven different alloalbumin types were characterized by structural study. Two previously unreported alloalbumin types were identified. In one type, which was present in a Caucasian family and designated Iowa City-1, aspartic acid at position 365 was replaced by valine (365 Asp----Val); this is the second reported mutation at this position. The other type present in a Japanese blood donor had the mutation 128 His----Arg. An unexpected finding was the presence in a single Japanese of a Naskapi-type alloalbumin (372 Lys----Glu), a variant that had previously been described only for certain Amerindian tribes in whom it occurs with a polymorphic frequency (greater than 1%) and in Eti Turks. An arginyl-albumin (-1 Arg, 1 Asp----Val) occurred in an American family. The other alloalbumin types identified were proalbumins Lille and Christchurch and albumin B that have a cumulative frequency of about 1:3500 in Caucasians probably because of the hypermutability of CpG dinucleotides at the mutated sites. All of the variants characterized in this study are point mutants, and the sites are spread throughout the albumin gene. However, about one-fourth of all known albumin mutations are clustered in the sequence segment from position 354 through 382.

Amino Acid Sequence

Effectiveness of the Imugard E leukocyte removal filter for preparation of leukocyte-poor concentrated red cells.

Concentrated red cells (CRC) were filtered through a new leukocyte removal filter, the Imugard E, which consists of a polyvinyl alcohol porous sheet. CRC were filtered through the Imugard E with neither priming before filtration nor rinsing after filtration. Leukocyte removal was 99.1 +/- 0.6, 99.6 +/- 0.3 and 99.6 +/- 0.4% on the 1st, 5th and 10th day after blood collection, respectively. Platelet removal was 96 +/- 2, 81 +/- 6 and 85 +/- 3% on the 1st, 5th and 10th day, respectively. Red cell recovery was 86 +/- 2, 86 +/- 1 and 86 +/- 1% on the 1st 5th and 10th day, respectively. Filtration time was 3.9 +/- 0.8, 5.8 +/- 0.9 and 6.1 +/- 0.8 min on the 1st, 5th and 10th day, respectively. Direct filtration of CRC through the Imugard E resulted in no significant changes in the ATP or 2,3-DPG concentrations, and no hemolysis due to filtration was noticed. It may be concluded that the Imugard E is a good filter that is simple to use and effective in leukocyte removal.

Blood Component Removal

Elicited antibody nature of human monoclonal protein with anti-streptolysin O activity--analysis with monoclonal anti-idiotype antibody.

Sera from 7 patients with multiple myeloma having antistreptolysin O (ASO) activity in high titers were detected by a streptolysin O (SLO) inhibition assay. However, activity was in low titer when assayed by a passive agglutination assay. The discrepancy between these 2 assays raised some doubts as to whether these monoclonal proteins (M.protein) bond to SLO in the same manner as elicited antibodies. Immunochemical analysis and idiotope analysis using monoclonal antibody to one of these M.proteins strongly suggest that M.protein with ASO activity bind to SLO in a manner similar to elicited antibody. The discrepancy between the 2 assays might be due to differences in the antigenic structure of different forms of the SLO molecule.

Antibodies

Studies on function of lymphocytes in NZB X NZW F 1 hybrid mice; autoantibody-producing cells and cytotoxicity of lymphocytes.

Several experiments were performed using B/W mice, experimental model of human systemic lupus crythematosus, with a view to explore the pathogenesis of autoimmune diseases. As a result of the Investigation by the immunocyte adherence method, autoantibody-producing cells were demonstrated at a ration of 1 to 4% in the spleen, thymus and lymph nodes of B/W mice, but nearly absent in the bone marrow. B/W mouse lymphocytes showed the cytotoxic activity to allgeneic target cells (L cells), but ANA positive sera from B/W mice also had a remarkable cytotoxic activity in the presence of the complement of a high concentration. It was also disclosed that there are Ig+ and theta-lymphocytes in the B/W mouse thymus at a nearly equal percentage, and the possible identity of the two was suggested.

Antibody-Producing Cells

Serial quantitative observations of leukemic and normal hematopoietic cells in the bone marrow of acute leukemia under chemotherapy.

In 87 cases of acute leukemia, leukemic and normal hematopoietic cell count in the bone marrow was serially observed, and the findings were used for evaluating the effectiveness of antileukemic agents and also for determining the grade of decrease in the marrow leukemic cell count required to start the proliferation of normal hematopoietic cells and to obtain complete remission of acute leukemia in adults.

Bone Marrow